-
Nadolol (SQ-11725) for Reproducible PK Assays
2026-09-19
Nadolol (SQ-11725) provides a practical non-selective beta-blockade tool for functional cardiovascular assays and transporter-aware disposition studies. This workflow connects receptor pharmacology with exposure, tissue distribution, and disease-state controls to improve interpretation in hypertension research, angina pectoris studies, and vascular headache research.
-
SGI-1027–Everolimus Synergy in Renal Cancer
2026-09-19
The reference study identifies SGI-1027 as a methuosis-inducing compound in renal cancer and shows that it cooperates with everolimus to suppress malignant phenotypes. Its central mechanistic insight is that lysosomal membrane permeability connects SGI-1027–associated vacuolation with apoptosis and GSDME-dependent pyroptosis, providing a rationale for combination treatment in everolimus-resistant disease models.
-
BRD4–RAC1 Co-targeting Rewires G9a Signaling
2026-09-18
The reference study shows that simultaneous inhibition of BRD4 and RAC1 suppresses growth, migration, stemness, and xenograft tumorigenesis across molecular subtypes of breast cancer. Its mechanistic contribution is to connect this response with disruption of the c-MYC–G9a–FTH1 axis and reduced HDAC1-associated chromatin regulation, providing a framework for interpreting G9a-directed experiments.
-
MEK–ERK Control of TERT in Human Stem Cells
2026-09-17
This preprint identifies a mechanistic link between MEK1/2–ERK1/2 signaling, c-Myc:MAX activity, and protection of the TERT promoter from polycomb-mediated repression in human embryonic stem cells. Its findings connect kinase signaling with local chromatin state and provide a framework for studying how MAPK pathway perturbation affects telomerase regulation.
-
NAT10-ac4C Regulation of Mouse Oocyte Maturation
2026-09-17
A Frontiers in Cell and Developmental Biology study identifies NAT10-mediated N4-acetylcytidine (ac4C) as a post-transcriptional regulator of mouse oocyte maturation in vitro. NAT10 knockdown reduced ac4C-associated signals and impaired first polar body extrusion, while TBL3 emerged as a candidate ac4C-binding protein for downstream investigation.
-
KPT330 and Cas9 Precision via mRNA Export Control
2026-09-17
The reference study identifies selective inhibitors of nuclear export, including KPT330, as indirect modulators of Cas9, base-editing, and prime-editing activity. Its central insight is that regulating Cas9 mRNA export can reduce unwanted editing without directly blocking the Cas9 protein, offering a distinct strategy for improving editing specificity in human cells.
-
Propranolol: From β-Blockade to Metabolic Insight
2026-09-16
Propranolol is a non-selective β-adrenergic receptor blocker with applications spanning cardiovascular regulation, neurobehavioral research, and metabolic biology. This article explains how adipose-tissue metabolomics can transform propranolol experiments from receptor-level observations into mechanistically interpretable translational models.
-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-09-15
The 2025 Frontiers in Immunology study shows that phenothiazines can strengthen macrophage antibacterial activity through coordinated lysosomal activation, autophagy, and reactive oxygen species accumulation. Its host-directed therapy framework offers a mechanistic basis for studying intracellular bacterial control without relying solely on direct antibiotic action.
-
Nintedanib (BIBF 1120): Mechanism and Research
2026-09-15
Nintedanib, also called BIBF 1120, is an orally active triple angiokinase inhibitor that blocks VEGFR, FGFR, and PDGFR signaling. Its strongest research rationale is pathway-level angiogenesis inhibition, while ATRX-deficient glioma findings support biomarker-aware RTK and PDGFR studies rather than a proven glioma indication.
-
JSH-23: A Practical NF-κB Inhibitor Workflow
2026-09-14
JSH-23 is a mechanistic NF-κB inhibitor for separating p65 transcriptional activity from upstream IκB degradation. This guide shows how to apply it in macrophage inflammation research, cytokine assays, inflammasome studies, and a cisplatin-induced acute kidney injury model while avoiding common interpretation errors.
-
Trametinib (GSK1120212) Experimental Workflows
2026-09-14
Trametinib (GSK1120212) is more than a viability reagent: it connects MEK1/2 target engagement with cell-cycle, apoptosis, and chromatin-level readouts. This workflow shows how to use it in cancer models and human pluripotent stem cells while reducing common dosing, solubility, and interpretation errors.
-
(-)-JQ1: Inactive Control for BET Assays
2026-09-13
(-)-JQ1 is a matched stereoisomeric control for separating BET-dependent biology from vehicle effects, cytotoxic stress, and assay artifacts. This workflow shows how to deploy it in epigenetics research, BRD4-dependent cell line studies, and pancreatic cancer screening models.
-
MK-5108 (VX-689) Assay Workflows
2026-09-12
MK-5108 (VX-689) enables selective Aurora A inhibition across biochemical, cell-based, and translational oncology workflows. This practical guide connects retinoblastoma evidence with dose-response design, cell cycle readouts, xenograft interpretation, and troubleshooting for reproducible cancer research.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-09-12
SGI-1027 combines direct DNA methyltransferase inhibition with DNMT1 protein depletion, making it useful for connecting CpG methylation changes to tumor suppressor gene reactivation. A response workflow that separates growth arrest from cell killing can reveal effects that a single endpoint viability assay may miss.
-
Nintedanib: ATRX-Aware Assay Design
2026-09-11
Nintedanib (BIBF 1120) is a triple angiokinase inhibitor whose VEGFR, FGFR, and PDGFR activity supports genotype-aware cancer assays. This article translates ATRX-deficient glioma findings into practical experimental decisions while distinguishing vascular, tumor-cell, and antifibrotic readouts.